Purple Biotech Starts Phase 2 Study for NT219 in Head and Neck Cancer
Ticker: PPBT · Form: 6-K · Filed: Jun 17, 2025 · CIK: 1614744
Sentiment: neutral
Topics: clinical-trial, oncology, drug-development
TL;DR
Purple Biotech kicks off Phase 2 for NT219 in head and neck cancer.
AI Summary
On June 17, 2025, Purple Biotech Ltd. announced the initiation of a Phase 2 study for its drug candidate NT219. This study will evaluate NT219 in patients diagnosed with head and neck cancer.
Why It Matters
This marks a significant step in the clinical development of NT219, potentially offering a new treatment option for head and neck cancer patients if successful.
Risk Assessment
Risk Level: medium — Clinical trial initiations carry inherent risks related to study outcomes, regulatory approvals, and market adoption.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- NT219 (drug_candidate) — Subject of Phase 2 study
- Head and Neck Cancer (medical_condition) — Indication for NT219 study
- June 17, 2025 (date) — Date of press release and study initiation announcement
FAQ
What is the primary purpose of the Phase 2 study announced by Purple Biotech?
The Phase 2 study aims to evaluate the efficacy and safety of NT219 in patients with head and neck cancer.
What is the name of the drug candidate being studied?
The drug candidate is named NT219.
What type of cancer is the Phase 2 study focused on?
The study is focused on patients with head and neck cancer.
When did Purple Biotech announce the initiation of this study?
Purple Biotech announced the initiation of the study on June 17, 2025.
What form was filed with the SEC to report this announcement?
This announcement was reported via a Form 6-K filing.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 17, 2025 regarding PURPLE BIOTECH LTD. (PPBT).